×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EBS – emergent biosolutions, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EBS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
07:30 am
ebs
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
Medium
Report
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
1/8
04:30 pm
ebs
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
Low
Report
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
1/8
08:00 am
ebs
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
Medium
Report
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
1/7
07:59 am
ebs
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Medium
Report
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
12/16
08:05 am
ebs
Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
12/12
08:30 am
ebs
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
Medium
Report
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
12/2
03:41 pm
ebs
Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at Weiss Ratings.
11/30
03:33 am
ebs
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street
Medium
Report
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street
Date
Time
Symbol
Company Name
Action
%Chg
10/29/2025
04:15 pm
ebs
emergent biosolutions, inc.
BEAT
Report
35.2%
emergent biosolutions, inc.
8/6/2025
04:15 pm
ebs
emergent biosolutions, inc.
BEAT
Report
32.5%
emergent biosolutions, inc.
5/7/2025
04:05 pm
ebs
emergent biosolutions, inc.
BEAT
Report
34.2%
emergent biosolutions, inc.
3/3/2025
04:23 pm
ebs
emergent biosolutions, inc.
BEAT
Report
-6.4%
emergent biosolutions, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
07:52 am
ebs
Form 8-K Emergent BioSolutions For: Jan 12
Medium
Report
Form 8-K Emergent BioSolutions For: Jan 12
1/7
04:27 pm
ebs
Form 144 Emergent BioSolutions Filed by: SULLIVAN LOUIS W
Medium
Report
Form 144 Emergent BioSolutions Filed by: SULLIVAN LOUIS W
12/22
06:23 pm
ebs
Form 144 Emergent BioSolutions Filed by: SULLIVAN LOUIS W
Low
Report
Form 144 Emergent BioSolutions Filed by: SULLIVAN LOUIS W
12/16
04:12 pm
ebs
Form 4 Emergent BioSolutions For: Dec 14 Filed by: Lowry Simon C
Low
Report
Form 4 Emergent BioSolutions For: Dec 14 Filed by: Lowry Simon C
12/12
08:30 am
ebs
Form 8-K Emergent BioSolutions For: Dec 12
Medium
Report
Form 8-K Emergent BioSolutions For: Dec 12
12/9
06:01 pm
ebs
Form 4 Emergent BioSolutions For: Dec 05 Filed by: Richard Ronald
Low
Report
Form 4 Emergent BioSolutions For: Dec 05 Filed by: Richard Ronald
12/5
04:04 pm
ebs
Form 144 Emergent BioSolutions Filed by: Richard Ronald
Low
Report
Form 144 Emergent BioSolutions Filed by: Richard Ronald
11/12
04:13 pm
ebs
Form 4 Emergent BioSolutions For: Nov 10 Filed by: DeGolyer Donald W
Medium
Report
Form 4 Emergent BioSolutions For: Nov 10 Filed by: DeGolyer Donald W
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/30
Emergent BioSolutions (EBS) Investor Presentation - Slideshow [Seeking Alpha]
14.7%
9/4 Form 8-K Emergent BioSolutions For: Aug 30 10.7%
3/10 Here's Why Emergent Biosolutions, BioMarin, and Nuvasive Fell on Monday [The Motley Fool] 10.2%
3/4 Emergent BioSolutions Selects Axiom Fusion eClinical Suite as Its Global eClinical Suite 9.2%
5/1 Form 8-K/A Emergent BioSolutions For: Apr 30 8.9%
4/23 Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19 8.5%
6/3 Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness 8.2%
4/27 Emergent Biosolutions Inc (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $71.00 price target on the stock. 7.2%
2/27 Form 4 Emergent BioSolutions For: Feb 25 Filed by: Strei Katherine 6.1%
3/11 Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease 5.3%
9/4 Form 8-K Emergent BioSolutions For: Aug 30 10.7%
3/10 Here's Why Emergent Biosolutions, BioMarin, and Nuvasive Fell on Monday [The Motley Fool] 10.2%
3/4 Emergent BioSolutions Selects Axiom Fusion eClinical Suite as Its Global eClinical Suite 9.2%
5/1 Form 8-K/A Emergent BioSolutions For: Apr 30 8.9%
4/23 Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19 8.5%
6/3 Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness 8.2%
4/27 Emergent Biosolutions Inc (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $71.00 price target on the stock. 7.2%
2/27 Form 4 Emergent BioSolutions For: Feb 25 Filed by: Strei Katherine 6.1%
3/11 Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease 5.3%
TOP News Decliners
3/13
Why These Drug Stocks Soared Today [The Motley Fool]
-15.6%
3/6 Form 3/A Emergent BioSolutions For: Mar 05 Filed by: Kirk Sean -10.5%
11/7 Emergent Biosolutions Inc (NYSE: EBS) had its "hold" rating re-affirmed by analysts at Cowen Inc. They now have a $67.00 price target on the stock. -10.0%
3/10 Here's Why Emergent BioSolutions Jumped Higher on Tuesday [The Motley Fool] -9.3%
3/31 Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™ -6.1%
4/20 Form 4 Emergent BioSolutions For: Apr 16 Filed by: El-Hibri Fuad -5.7%
10/21 Emergent BioSolutions to Host 2019 Analyst & Investor Day -5.2%
9/10 Form 4 Emergent BioSolutions For: Sep 09 Filed by: Zoon Kathryn C -4.9%
3/2 Form 4 Emergent BioSolutions For: Feb 27 Filed by: Bailey Sue -4.6%
10/7 Here’s Why Emergent BioSolutions Stock Climbed 19.4% in September [The Motley Fool] -4.2%
3/6 Form 3/A Emergent BioSolutions For: Mar 05 Filed by: Kirk Sean -10.5%
11/7 Emergent Biosolutions Inc (NYSE: EBS) had its "hold" rating re-affirmed by analysts at Cowen Inc. They now have a $67.00 price target on the stock. -10.0%
3/10 Here's Why Emergent BioSolutions Jumped Higher on Tuesday [The Motley Fool] -9.3%
3/31 Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™ -6.1%
4/20 Form 4 Emergent BioSolutions For: Apr 16 Filed by: El-Hibri Fuad -5.7%
10/21 Emergent BioSolutions to Host 2019 Analyst & Investor Day -5.2%
9/10 Form 4 Emergent BioSolutions For: Sep 09 Filed by: Zoon Kathryn C -4.9%
3/2 Form 4 Emergent BioSolutions For: Feb 27 Filed by: Bailey Sue -4.6%
10/7 Here’s Why Emergent BioSolutions Stock Climbed 19.4% in September [The Motley Fool] -4.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: